SCHEMBL810397

SCHEMBL810397

COc1cccc(COc2ccc(Sc3ccc(O)cc3)c(Nc3ncnc4ncccc34)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.55
AKT2 P31751 1/20 0.55
ABCG2 Q9UNQ0 3/20 0.43
EGFR P00533 3/20 0.39
ERBB2 P04626 2/20 0.39
GCK P35557 1/20 0.39
MAOB P27338 4/20 0.38
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KDR P35968 1/20 0.37
KMT2A Q03164 1/20 0.37
CSF1R P07333 1/20 0.37
PDGFRB P09619 1/20 0.37
FLT4 P35916 1/20 0.37
FLT3 P36888 1/20 0.37
SLC2A1 P11166 1/20 0.36
SLC2A4 P14672 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810323 0.92 PIM1 (0.57) PIM1AKT2ABCG2EGFRERBB2
SCHEMBL810060 0.91 PIM1 (0.58) PIM1AKT2ABCG2EGFRERBB2
SCHEMBL810273 0.90 PIM1 (0.60) PIM1AKT2EGFRERBB2MEN1
SCHEMBL810912 0.89 PIM1 (0.58) PIM1AKT2EGFRERBB2MAOB
SCHEMBL810939 0.89 PIM1 (0.54) PIM1AKT2EGFRERBB2MAOB
SCHEMBL810399 0.89 PIM1 (0.71) PIM1AKT2ABCG2EGFRERBB2
SCHEMBL810344 0.87 PIM1 (0.59) PIM1AKT2ABCG2EGFRERBB2
SCHEMBL810307 0.87 PIM1 (0.52) PIM1AKT2ABCG2EGFRERBB2
SCHEMBL821092 0.86 PIM1 (0.57) PIM1AKT2EGFRERBB2MAOB
SCHEMBL811361 0.85 PIM1 (0.59) PIM1AKT2EGFRERBB2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885ABCG2 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.